A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.
Weston Park Hospital, Sheffield, England, United Kingdom
St. James's Hospital, Leeds, England, United Kingdom
Institut Claudius Regaud, Toulouse, France
Hopital Haut Leveque, Pessac, France
CHRU de Nancy - Hopitaux de Brabois, Vandoeuvre-Les-Nancy, France
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
Royal Adelaide Hospital, Adelaide, South Australia, Australia
University of Ljubljana, Ljubljana, Slovenia
Temple University Cancer Center, Philadelphia, Pennsylvania, United States
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States
Royal United Hospital, Bath, England, United Kingdom
Kent and Canterbury Hospital, Canterbury, England, United Kingdom
Saint Richards Hospital, Chichester, England, United Kingdom
Children's Hospital and Health Center - San Diego, San Diego, California, United States
Indiana University Cancer Center, Indianapolis, Indiana, United States
Fairview University Medical Center - University Campus, Minneapolis, Minnesota, United States
Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.